These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34536161)

  • 1. How FGF23 shapes multiple organs in chronic kidney disease.
    Leifheit-Nestler M; Haffner D
    Mol Cell Pediatr; 2021 Sep; 8(1):12. PubMed ID: 34536161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented Fibroblast Growth Factor-23 Secretion in Bone Locally Contributes to Impaired Bone Mineralization in Chronic Kidney Disease in Mice.
    Andrukhova O; Schüler C; Bergow C; Petric A; Erben RG
    Front Endocrinol (Lausanne); 2018; 9():311. PubMed ID: 29942284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease-A Pediatric Perspective.
    Grund A; Sinha MD; Haffner D; Leifheit-Nestler M
    Front Pediatr; 2021; 9():702719. PubMed ID: 34422725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I; Haffner D; Leifheit-Nestler M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23 Actions in CKD-MBD and other Organs During CKD.
    Sun T; Yu X
    Curr Med Chem; 2023; 30(7):841-856. PubMed ID: 35761503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder.
    Akiyama K; Kimura T; Shiizaki K
    Int J Endocrinol; 2018; 2018():5282389. PubMed ID: 29780418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease.
    Jimbo R; Shimosawa T
    Int J Hypertens; 2014; 2014():381082. PubMed ID: 24678415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of DMP1 in CKD-MBD.
    Martin A; Kentrup D
    Curr Osteoporos Rep; 2021 Oct; 19(5):500-509. PubMed ID: 34331667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What would we like to know, and what do we not know about fibroblast growth factor 23?
    Cozzolino M; Galassi A; Apetrii M; Covic A
    J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
    Komaba H
    Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral metabolism and cardiovascular disease in CKD.
    Fujii H; Joki N
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paracrine Effects of FGF23 on the Heart.
    Leifheit-Nestler M; Haffner D
    Front Endocrinol (Lausanne); 2018; 9():278. PubMed ID: 29892269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease.
    Dussold C; Gerber C; White S; Wang X; Qi L; Francis C; Capella M; Courbon G; Wang J; Li C; Feng JQ; Isakova T; Wolf M; David V; Martin A
    Bone Res; 2019; 7():12. PubMed ID: 31044094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone and Mineral Metabolism in Children with Nephropathic Cystinosis Compared with other CKD Entities.
    Ewert A; Leifheit-Nestler M; Hohenfellner K; Büscher A; Kemper MJ; Oh J; Billing H; Thumfart J; Stangl G; Baur AC; Föller M; Feger M; Weber LT; Acham-Roschitz B; Arbeiter K; Tönshoff B; Zivicnjak M; Haffner D
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32413117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia.
    Figurek A; Rroji M; Spasovski G
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.